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Abstract: Endoglin (CD105) is an accessory component of the TGF-β receptor complex, which is
expressed in a number of tissues and over-expressed in the endothelial cells of tumor neovasculature.
Targeting endoglin with immunotoxins containing type 2 ribosome-inactivating proteins has proved
an effective tool to reduce blood supply to B16 mice tumor xenografts. We prepared anti-endoglin
immunotoxin (IT)—containing recombinant musarmin 1 (single chain ribosome-inactivating proteins)
linked to the mouse anti-human CD105 44G4 mouse monoclonal antibody via N-succinimidyl
3-(2-pyridyldithio) propionate (SPDP). The immunotoxin specifically killed L929 fibroblast mouse cells
transfected with the short form of human endoglin with IC50 values in the range of 5ˆ 10´10 to 10´9 M.
Keywords: recombinant musarmin; endoglin; CD105; 44G4; anti-endoglin monoclonal antibody;
anti-tumor therapy; cancer therapy
1. Introduction
Attacking cancer cells with drugs can be performed either directly by targeting cells or indirectly
by destroying the new blood vessels induced by the tumor which each support hundreds of
cancer cells. The latter strategy is known as the antiangiogenic approach to cancer therapy [1].
This may be performed using cytotoxic agents such as antibodies aimed at the vasculature targets
and immunotoxins (ITs). ITs are formed by at least two parts, one a carrier, such as an antibody or
a ligand able to recognize and bind specific targets, and the other a toxic moiety, such as plant
or bacterial toxins, which are able to kill target cells [2–5]. In conventional ITs, both parts are
linked by chemical means, while in recombinant ITs, the two parts are fused by genetic engineering.
In conventional ITs, a number of ribosome-inactivating proteins (RIPs) have been used as a toxic
moiety [5]. In recombinant ITs, bacterial toxins such as those of Pseudomonas exotoxin or from diphtheria
toxin and plant ribosome-inactivating proteins such as gelonin have been used [6–8].
The TGF-β co-receptor endoglin (CD105) is expressed in several mammalian tissues related to
the proliferation of new vasculature [9]. Endoglin is considered a marker for evaluating microvessel
density in tumors [10], and has also been reported as a target of tumor neovasculature for cancer
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therapy [11–14]. Recent research has supported the idea that silencing it promotes a significant
antitumor effect on murine mammary adenocarcinoma [15].
Targeting endoglin over-expressed in tumor neovasculature has been used for therapeutic
purposes with anti-endoglin antibodies [16], endoglin-targeted radioimmunotherapy [17],
and anti-endoglin antibody–containing ITs [18]. Efficient conventional anti-endoglin ITs containing
ricin A-chain [19] and the type 2 RIPs nigrin b [12,20] and ebulin l [21] have been constructed. In the
present work, we report proof of the validity of the new IT (rMU1-44G4), containing rMU1 as a
toxic moiety linked to an anti-human CD105 monoclonal antibody (44G4), on cultured mouse L929
fibroblasts transfected with the short form of CD105 [22]. rMU1, a recombinant form expressed in
Escherichia coli, of musarmin 1 (MU1) present in bulbs of the plant Muscari armeniacum L. Miller was able
to retain full activity when tested on mammalian ribosomes both in translation and in N-glycosidase
activities [23].
2. Results and Discussion
Preparation of the rMU1 from the cytosolic insoluble fraction (inclusion bodies), upon extraction,
solubilization and refolding, yielded 20 mg/L of rMU1 [23]. As shown in Figure 1 (left), the rMU1
batch used to construct immunotoxins was homogeneous as judged by gel filtration through Superdex
75, giving a symmetric peak, and SDS-PAGE, with a single band of apparent Mr of 28,000 Da. As also
shown in Figure 1 (right), rMU1 promotes the release of the Endo rRNA fragment, which is diagnostic
of RIP N-glycosidase action on the 28S rRNA. For comparison purposes, we also include type 1 RIP
Saporin S5 [24] in the experiment.
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44G4 as reported  for  the other 44G4‐containing  immunotoxin ebulin‐44G4  [21]. After  the reaction 
between  the  activated  rMU1  and  the  activated  mAb,  the  reaction  mixtures  were  subjected  to 
Figure 1. Molecular characterization of rMU1. Left panel: Superdex 75 chromatography of rMU1 and
SDS-PAGE analysis of the preparation (inset); the horizontal bar indicates the collected factions. Right
panel: N-glycosidase of rMU1 on rabbit reticulocyte ribosomes; A: control; B: soluble rMU1; C: rMU1
from solubilized inclusion bodies; D: Saporin-S5; (+) indicates the treatment of the lysates with acid
aniline and (*) indicates the Endo fragment; numbers on the left indicate base pairs and on the right the
rRNA type.
The first step in immunotoxin construction was to determine the number of sulfide residues
introduced by the linker into the recombinant RIP and their effect on RIP activity. The study was
conducted with rMU1 and N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) as the linker. It was
found that 1–1.5–SH residues per molecule of RIP was the best situation (data not shown). With that
ratio, the IC50 of rMU1 on rabbit reticulocyte lysates was 30 nM.
Toxins 2016, 8, 184 3 of 10
Toxins 2016, 8, 184  3 of 10 
 
chromatography  through Sephacryl‐S200  to  isolate  the  reaction products. As shown  in  the upper 
panel  of  Figure  2,  rMU1 was  conjugated with  44G4,  giving  species  that moved  in  the  front  as 
polymers. SDS‐PAGE analysis at different  acrylamide percentages  revealed  that peaks  contained 
different chemical species from high molecular weight conjugates to isolated rMU1 and 44G4 (Figure 
2, lower panel A). The size indicated in lower panel A of Figure 2 was estimated from the expected 
molecular weights  for  different  stoichiometries  between  rMU1  and  44G4.  Fractions  collected  as 
conjugates suitable for testing as cytotoxic species were those indicated by the C bar that were mixed 
and used as IT. D fractions were not used since they contained free 44G4 mAb which could compete 
with  the  immunotoxin  for binding  to CD105. As shown  in Figure 3A, SDS‐PAGE analysis of  this 
mixture in the absence of 2‐ME revealed conjugates with RIP/mAb stoichiometries of 1:1, 2:1, 3:1, 4:1. 
The IT used in the cell viability assays was a mixture of these species but essentially contained the 1:1 
and  2:1  species. We  further  analyzed  the  components  of  the  immunotoxin  by  SDS‐PAGE  in  the 
presence of 2‐ME to reduce disulphide linking. As shown in Figure 3B, electrophoresis revealed that 
reduction  allowed  the  complete  separation  of  both  components  of  the  IT  rMU1  and  44G4. 
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Figure 2. Purification (upper panel) and SDS-PAGE analysis (lower panel) of the rMU1-44G4
immunotoxin. Upper panel: The reaction mixtures were carried out as indicated in Materials and
Methods and purified by gel filtration chromatography on Superdex 200 HiLoad. Letters in the
chromatogram of the upper panel indicate peaks analyzed by SDS-PAGE; the fractions collected
in each peak were: B (high molecular weight aggregates of 44G4 and RMU1), 135–140 mL; C1
(medium molecular weight conjugates rMU1-44G4), 150–155 mL; C2, (low molecular weight conjugates
rMU1-44G4), 165–170 mL; D1 (low molecular weight conjugates rMU1-44G4), 170–175 mL; D2 (low
molecular weight conjugates rMU1-44G4), 175–180 mL; E (rMU1 tetramer), 185–190 mL; F (rMU1
trimer), 192–207 mL; G (rMU1 dimer), 207–230 mL; H (rMU1), 235–260 mL. Both C1 and C2 were mixed
and used as immunotoxin; Lower panel: Proteins contained in the indicated peaks were analyzed
by SDS-PAGE using three different concentrations of acrylamide: 7.5% (w/v) (A); 10% (w/v) (B);
18% (w/v) (C); numbers on the right indicate the apparent Mr; numbers in parentheses indicate the
estimated size. The amount of protein loaded into each well was: 30 micrograms in lanes B, C1, C2, D1,
D2; four micrograms in lane H; 10 micrograms in lanes G, F and E. Numbers on the right indicate the
corresponding apparent Mr values of the standards.
Then 44G4 mAb was selected as anti-human CD105 since it is highly specific for human CD105 [22].
It was also derivatized with SPDP to introduce two to three sulfhydryl groups per molecule of 44G4
as reported for the other 44G4-containing immunotoxin ebulin-44G4 [21]. After the reaction between
the activated rMU1 and the activated mAb, the reaction mixtures were subjected to chromatography
through Sephacryl-S200 to isolate the reaction products. As shown in the upper panel of Figure 2,
rMU1 was conjugated with 44G4, giving species that moved in the front as polymers. SDS-PAGE
analysis at different acrylamide percentages revealed that peaks contained different chemical species
from high molecular weight conjugates to isolated rMU1 and 44G4 (Figure 2, lower panel A). The size
indicated in lower panel A of Figure 2 was estimated from the expected molecular weights for different
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stoichiometries between rMU1 and 44G4. Fractions collected as conjugates suitable for testing as
cytotoxic species were those indicated by the C bar that were mixed and used as IT. D fractions were
not used since they contained free 44G4 mAb which could compete with the immunotoxin for binding
to CD105. As shown in Figure 3A, SDS-PAGE analysis of this mixture in the absence of 2-ME revealed
conjugates with RIP/mAb stoichiometries of 1:1, 2:1, 3:1, 4:1. The IT used in the cell viability assays
was a mixture of these species but essentially contained the 1:1 and 2:1 species. We further analyzed the
components of the immunotoxin by SDS-PAGE in the presence of 2-ME to reduce disulphide linking.
As shown in Figure 3B, electrophoresis revealed that reduction allowed the complete separation of both
components of the IT rMU1 and 44G4. Conjugation of rMU1 with the mAb reduced its IC50 value on
rabbit reticulocyte lysates from 14 ng/mL (approx. 5.2 ˆ 10´10 M) to 24 ng/mL (approx. 9 ˆ 10´10 M).
Chemical conjugation of proteins with biological activity might affect and reduce and even eliminate
their activities. In our case, the coupling of 44G4 to rMU1 did not significantly alter the translational
inhibitory activity on translation by rabbit reticulocyte lysates. This indicated that, even after being
linked to 44G4, the modified RIP molecules have free access to the substrate target loop of the 28S
rRNA in the large ribosomal subunit.
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Figure 3. Analysis of rMU1-44G4 IT by SDS-polyacrylamide gel electrophoresis in the absence (A)
or presence (B) of 2-mercaptoethanol (2-ME). (A) Electrophoresis in the absence of 2-ME was carried
out with 7.5% (w/v) polyacrylamide gels; the rMU1/44G4 ratio is indicated on the left of the picture;
(B): Electrophoresis in the presence of 2-ME was carried out with 18% (w/v) polyacrylamide gels.
The numbers on the right of both gels indicated the apparent Mr of the markers used. The numbers on
the left indicate the RIP/mAb stoichiometries.
Further, we assayed the cytotoxicity of the rMU1-44G4 IT on L929-shCD105+ mouse cells as a
reduction of cell viability using the WST-1 reagent rather than inhibition of protein synthesis since
viability is more sensitive to inhibitors than translation, most likely due to the pleiotropic cellular effects
of RIPs [20,25]. As shown in Figure 4, rMU1-44G4 IT kills cells with an IC50 value of 3.9 ˆ 10´10 M for
L929-shCD105+ cells and >10´7 M for control untransfected L929 cells. Further, neither 44G4 mAb nor
rMU1 alone display inhibitory action at concentrations such as those required to see full inhibition by
the IT. The therapeutic window of IC50 between the CD105-expressing cells and the parental cells was
over three orders of magnitude. These results point to the high specificity of the present IT for CD105.
The cytotoxicity of the present IT compares well with other ITs containing anti-CD105 antibodies
such as those prepared with type 2 nigrin b or ebulin l as RIPs [12,20,21]. In vivo administration of
anti-CD105 mAbs [13,26] and an anti-CD105-nigrin b IT [20] enabled murine tumors to be reduced and
eliminated. CD105 has been proposed for targeted cancer treatment [11,13]. However, some concerns
have arisen due to the presence of said marker in specialized cells, thus necessitating the need for
further research. Kays and co-workers recently reported that CD105 is also a marker for human
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long-term repopulating hematopoietic stem cells [27]. Accordingly, some toxicity of anti-CD105 ITs
on CD105-expressing human cells both in vitro and in vivo would be expected. In this line, previous
results indicate that the IT 44G4-nigrin b is active on cultured L929-hCD105+ mouse fibroblast with
an IC50 of 6 ˆ 10´10 M and on human umbilical vein endothelial cells (HUVEC cells) with an IC50
of 6.4 ˆ 10´9 M [20]. RIP delivery into the cell is thus mandatory for the inhibitory action of the
IT, and such transport is fully mediated by the antibody binding to CD105 and internalization of
the CD105-IT complex. This also suggests that the intracellular traffic of such complexes does not
seem to be much affected by the type of RIP (type 2, type 1 or recombinant type 1 RIPs) linked to the
antibody. However, since the precise mechanism of said complex pathway is not fully understood,







Clinical  trials have been  conducted  to  test  the  efficiency of  several  immunotoxins  in  vivo  in 
cancer patients, for instance in those suffering from leukemia and lymphoma [28–30]. Major obstacles 
encountered  in  the  in  vivo  use  of  ITs  lie  in  the  appearance  of  vascular  leak  syndrome  and  the 
immunogenicity of IT components [31]. Attempts to circumvent vascular leak syndrome have been 
carried out, such as through chemical modifications of the RIP such as blocked ricin [32], the use of 










endoglin  (upper panel)  and parental L929 mouse  fibroblasts  (lower panel). Growing  cultures  of 





Figure 4. Cytotoxicity of the r U1-44G4 i unotoxin on L929 expressing the short for of hu an
endoglin (upper panel) and parental L929 mouse fibroblasts (lower panel). Growing cultures
of transfected L929-hCD105+ and parental L929 cells were incubated for 3 h, either with rMU1,
immunotoxin or 44G4 and the viability of cells was assayed with the WST-1 reagent as indicated in the
Materials and Methods Section. Vertical bars indicate the ˘SEM (n = 3).
Clinical trials have been conducted to test the efficiency of several immunotoxins in vivo in cancer
patients, for instance in those suffering from leukemia and lymphoma [28–30]. Major obstacles
encountered in the in vivo use of ITs lie in the appearance of vascular leak syndrome and the
immunogenicity of IT components [31]. Attempts to circumvent vascular leak syndrome have been
carried out, such as through chemical modifications of the RIP such as blocked ricin [32], the use of
different RIPs, and the use of fusion proteins containing RIP domains [5,6]. In order to minimize
neutralization, several strategies, such as reducing the size and humanization of the antibodies and
preparing fusion proteins with reduced immunogenicity, have been used [33]. Moreover, research into
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the usefulness of anti-CD105 ITs will progress through technical advances in the delivery and efficiency
testing of anti-CD105 drugs. In this line, developing a novel genetically engineered mouse model
expressing humanized CD105 may enable more efficient therapy agents to be found [34]. Additionally,
the present results open up the possibility of developing fusion proteins carrying the cytotoxic domain
of rMU1 and binding domains specific for plasma membrane–inserted CD105.
In summary, cytotoxic anti-CD105 targeting therapy with an IT using a fully active recombinant
type 1 RIP such as rMU1 increases the arsenal of tools for research into experimental cancer therapy.
Further work will address the effects of the in vivo administration of the present IT to tumor-bearing
mice, the pharmacokinetics and the immunogenic potential.
3. Materials and Methods
3.1. Chemicals, Reagents and Biological Materials
Common chemicals and biological materials were purchased from the same sources as reported
elsewhere [12]. WST-1 reagent was from Roche Diagnostics, S.L. Life Science (Sant Cugat del Vallés,
Spain) N-succinimidyl 3-(2-pyridyldithio)propionate was obtained from Sigma Chemical Co (St. Louis,
MO, USA). Saporin S5 was a generous gift from Prof. F. Stirpe (Università di Bologna, Bologna,
Italy). The hybridoma cell line 44G4 producing a monoclonal antibody (mAb) to hCD105 was kindly
provided by Dr. Michelle Letarte through Dr. C. Bernabéu (Centro de Investigaciones Biologicas, CSIC,
Madrid, Spain). It was grown as described elsewhere: Purification of 44G4 mAb was performed by
protein A-Sepharose chromatography as described previously [21]. Mouse fibroblasts L929-shCD105+
expressing the short human form of CD105 were a generous gift from Dr. C. Bernabéu [35].
3.2. Recombinant Musarmin 1 (rMU1)
Highly purified rMU1 was prepared as reported previously [22]. Briefly, the strategy was
as follows. The cloning vector containing the MU1 gene flanked by NcoI at the N-terminus
and Hind III at the C-terminal sequence was amplified by PCR, ligated into pUC18 plasmid and
sub-cloned. The plasmid containing MU1 gene was digested to release a restriction fragment of
830 bp which was then ligated to the expression plasmid pET-25b. The pET-25+MU1 plasmid was
then introduced into the expression Escherichia coli strain BL21(DE3)pLysS. Expression was induced
by isopropyl-β-D-thiogalactoside and the cells from the bacterial cultures were isolated, lysed by
freeze-thawing and centrifuged to isolate the insoluble protein fraction containing the inclusion
bodies. They were solubilized with cetyltrimethylammonium bromide and the insoluble material
was removed by centrifugation. The resulting supernatant was dialyzed to remove the detergent and
to allow refolding of rMU1. The protein was then purified from said supernatant by NaCl-gradient
ion-exchange chromatography on SP-Sepharose followed by gel filtration through Superdex 75 GE
Healthcare Europe GmbH (Barcelona, Spain). The yield was around 20 mg/L of bacterial culture of
solubilized refolded rMU1.
3.3. Activation of the 44G4 Monoclonal Antibody
The 44G4 mouse monoclonal antibody (5 mg) was dissolved in 50 mM Na-borate (pH 9.0) buffer
to obtain a concentration of 1.3 mg/mL. Five molar excess of the linker SPDP was added to the protein
solution and the mixture was incubated for 1 h at 30 ˝C. Said solution was then dialyzed overnight
at 4 ˝C against a 4 L of solution of 140 mM NaCl containing 5 mM sodium phosphate (pH 7.5).
To determine the number of sulfhydryl groups per molecule, the derivatized protein was treated with
50 mM dithiothreitol to reduce the disulphide bridges and the released pyridine-2-thione was then
determined at A343 (a control of absorption of pyridine-2-thione at A280 must be carried out), and
compared to the derivatized protein. The ratio of linker bound to 44G4 was 1.9.
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3.4. Preparation of Activated rMU1
rMU1 (15 mg) was dissolved in 50 mM Na-borate (pH 9.0) buffer to obtain a concentration of
4–5 mg/mL and activated with SPDP in the same way as for 44G4 monoclonal antibody and in a final
volume of 1.5 mL. The activated rMU1 was dialyzed overnight at 4 ˝C against 4 L of 140 mM NaCl
solution containing 5 mM sodium phosphate (pH 7.5). The ratio of the SPDP linker to the recombinant
protein was determined as for 44G4 mAb, and was in the range of 1.0.
3.5. Preparation and Purification of rMU1-44G4 IT
First 3.7 mg of the activated 44G4 monoclonal antibody was reduced with 50 mM dithiothreitol for
30 min at room temperature to unblock the sulfhydryl groups. The protein was then chromatographed
through a Sephadex G-25 column (bed volume 28 mL) GE Healthcare Europe GmbH (Barcelona,
Spain) to remove the released low molecular weight material. That column previously equilibrated
with a solution of 140 mM NaCl containing 5 mM sodium phosphate (pH 7.5) was eluted with the
same solution. The protein was collected on 11 mg of the previously SPDP-activated and dialyzed
rMU1. The conjugation reaction was carried out for 16 h with gentle stirring at room temperature.
The solution was then concentrated to 7 mL with Amicon (YM10 membrane) Sigma Chemical Co
(St. Louis, MO, USA), and centrifuged for 10 min at 13,000ˆ g at 4 ˝C. The clear supernatant was
chromatographed through a Superdex 200-HL column GE Healthcare Europe GmbH (Barcelona, Spain)
equilibrated with 140 mM NaCl containing 5 mM sodium phosphate (pH 7.0), and eluted with the
same buffer solution at 2 mL/min, collecting fractions of 5 mL. Fractions containing the immunotoxin
were collected, pooled and further concentrated with Amicon YM10 up to 1 mL. The immunotoxin
was then dialyzed, aliquoted, and stored at ´80 ˝C. The yield of immunotoxin under our conditions
was in the range of 1.2 mg.
3.6. Assay of Cell-Free Protein Synthesis
Cell-free protein synthesis was determined with a coupled transcription-translation in vitro assay
using the rabbit reticulocyte lysate system as described elsewhere [36]. The reaction mixture contained
in 8 µL was the following: 5 µL rabbit reticulocyte lysate, 6.5 U ribonuclease inhibitor, 4 U T7 RNA
Polymerase, 0.25 µg Luciferase T7 plasmid, 0.4 mM rNTP’s each, 2 µM protein amino acids each,
10 mM Tris-HCl (pH 7.8), 0.2 mM spermidine, 28 mM KCl, 1 mM MgCl2 and nuclease-free water.
The reaction mixtures were incubated at 30 ˝C for 10 min and chilled on ice. A volume of 2 µL of
either water or dilutions of rMU1 of the rMU1-44G4 was added to the test tubes and samples were
incubated at 30 ˝C for 30 min. A volume of 25 µL of water was added to the sample and 25 µL of the
mixed dilution was removed and added to 25 µL of room temperature Luciferase Assay Reagent in a
luminometer tube. The relative luciferase activities of the samples were determined in a Luminova
1254 luminometer (BIO ORBIT, Turku, Finland) for 10 s with an initial delay of 2 s. A volume of 2 µL
of water was added to the reaction mixture to determine background luminescence.
3.7. Cytotoxicity of the rMU1-44G4 IT on L929-hCD105+ Cells
The cytotoxic activity of the immunotoxin, assessed as cell viability [19,20], was performed as
follows. Briefly, 96-well plates were seeded with 3 ˆ 103 cells and 100 µL of culture medium per well.
Culture medium for parental L929 cells was RPMI 1640 supplemented with 2 mM L-glutamine,
100 units/mL penicillin, 100 µg/mL streptomycin and 10% (v/v) heat-treated fetal calf serum.
Transfected L929-CD105+ cells were incubated with the same culture medium as the parental ones but
containing 400 µg/mL of geneticin. Incubation was for 24 h at 37 ˝C under 5% CO2. Wells were then
washed with culture medium without fetal calf serum and then 100 µL of culture medium containing
fetal calf serum was added and incubated with the corresponding amount of RIP or conjugate for 48 h
at 37 ˝C under 5% CO2. At the end of incubation, 10 µL of WST-1 reagent (Roche Diagnostics, S.L.
Life Science, Sant Cugat del Vallés, Spain) was added to each well and the plate was gently shacked
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for 2 min and then incubated for 2 h at 37 ˝C under 5% CO2. Reduction of the WST-1 reagent was
quantified at 450 nm in an ELISA reader (Multiskan, Thermo Fisher Scientific, Alcobendas, Spain).
Each experimental point was carried out in triplicate.
3.8. Other Procedures
Apparent Mr was determined by polyacrylamide gel electrophoresis in the presence of SDS
(SDS-PAGE) and stained with Coomasie brilliant blue as described previously [31]. The electrophoresis
Mr markers used were: myosin (apparent Mr 205,000); phosphofructoquinase (apparent Mr 116,000);
bovine serum albumin (apparent Mr 68,000); L-glutamate dehydrogenase (apparent Mr 54,000); alcohol
dehydrogenase (apparent Mr 37,000); carbonic anhydrase (apparent Mr 29,000); trypsin inhibitor
(apparent Mr 20,100). Protein concentrations were determined by spectrophotometry [22].
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The following abbreviations are used in this manuscript:
2-ME 2-mercaptoethanol
mAb monoclonal antibody
RIP ribosome inactivating protein
rMU1 recombinant musarmin 1
rNTP‘s ribonucleotides
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis
SPDP N-succinimidyl 3-(2-pyridyldithio)propionate
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